Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort

Clinical Therapeutics

Volumn 24, Issue 2, 2002, Pages 237-248

  Kotzan, Jeffrey A ^a   Maclean, Ross ^b   Wade, William ^a   Martin, Bradley C ^a   Iami, Hirohisa ^b   Tadlock, Gary ^c   Gottlieb, Marc ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Blue Cross Blue Shield of Georgia   (United States)

Author keywords

Antidepressant therapy; Combination drug therapy; Health maintenance organization; Polypharmacy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG UTILIZATION; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; POLYPHARMACY; PRESCRIPTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

EID: 0036195705     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85020-2     Document Type: Article

References (30)

1. Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review
2. Serotonin syndrome: History and risk
3. Antidepressant drugs: Disturbing and potentially dangerous adverse effects
4. Drug interactions of clinical significance with selective serotonin reuptake inhibitors
5. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: Antidepressants and antipsychotics and the cytochrome P450 system
6. Pharmacokinetics of selective serotonin reuptake inhibitors
7. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants
8. Fluoxetine drug-drug interactions. II
9. Interactions between sertraline and tricyclic antidepressants
10. Paroxetine: An overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression
11. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
12. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: How often does it really happen?
13. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications
14. Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors
15. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression
16. Selective serotonin- reuptake inhibitors: An update
17. Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder
18. Meta-analysis of benzodiazepine use in the treatment of insomnia
19. Zolpidem for persistent insomnia in SSRI-treated depressed patients
20. Zolpidem, a valuable alternative to benzodiazepine hypnotics for chronic insomnia?
21. Pathophysiology and management of insomnia during depression
22. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice
23. Response to an open trial of a second SSRI in major depression
24. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
25. Polypharmacy
26. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpa- tients with polypharmacy
27. Reducing polypharmacy in the elderly. A controlled trial of physician feedback
28. Death and death rates for the 10 leading causes of death in specified age groups